{
  "docId": "019de075-7539-774f-abd7-26734f481c17",
  "docSlug": "efb32a48c20b71d9dd70ea37e2f1bc4b",
  "documentTitle": "argenx SE | Investor Presentation Deck | 26 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 26,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "Kaplan-Meier curve shows probability of no relapse over 48 weeks for Vyvgart Hytrulo vs Placebo.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7539-774f-abd7-26734f481c17/13",
  "deckHref": "/decks/019de075-7539-774f-abd7-26734f481c17",
  "deckJsonHref": "/decks/019de075-7539-774f-abd7-26734f481c17.json",
  "deckAnchorHref": "/decks/019de075-7539-774f-abd7-26734f481c17#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.43,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Kaplan-Meier curve of probability of no relapse",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5fc1c79-6e8a-4b5a-b444-5590d576921f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.14,
        "y": 0.295
      },
      "kind": "metric",
      "text": "67% - 78%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ef4d697-b58d-4894-8976-8e593ba79516",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.14,
        "y": 0.58
      },
      "kind": "metric",
      "text": "HR: 0.39 P = 0.000039",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe777273-b3b1-4e53-955f-2f98f99ac519",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.04,
        "y": 0.375
      },
      "kind": "paragraph",
      "text": "Response rates demonstrate IgG autoantibodies play significant role in underlying CIDP biology",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c8ab007-4a60-42a3-a9e9-6dbc9263a517",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.04,
        "y": 0.71
      },
      "kind": "paragraph",
      "text": "61% lower risk of relapse based on time to first adjusted INCAT deterioration with VYVGART Hytrulo compared to placebo",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e01a1607-c8f7-45c0-8d79-c25f6c487453",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "ADHERE: Opportunity to Transform CIDP Patient Experience",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55a91061-3416-4939-a540-27e4f7f8769d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 11,
      "beatId": "af5b9698-0715-42c3-ab3c-5f550442d8f0",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "The Goal",
      "beatSlug": "quest-the-goal",
      "evidence": "Slides 11-16 outline the company's pipeline expansion and growth opportunities.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 11,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "b3089ade-03b9-4666-a74c-3c80f7a68561",
      "evidence": "The document outlines various pipeline indications and growth opportunities.",
      "position": 1,
      "objective": "Presenting pipeline opportunities for growth and expansion",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}